Pharmacology Module 1: Comprehensive Study Notes

Fundamental Definitions in Pharmacology

  • Pharmacokinetics: The study of how the body affects a drug, specifically focusing on how it is absorbed, distributed, metabolized, and excreted.

  • Pharmacodynamics: The study of how the drug affects the body and what it does at its site of action.

  • Therapeutic Class: A group of drugs categorized based on what they are used to treat (e.g., antihypertensives).

  • Pharmacological Class: A group of drugs categorized based on their mechanism of action or how they work within the body (e.g., calcium channel blockers).

  • Prototypes: An individual drug model or common example used to represent and compare with other drugs in a specific drug class.

  • Chemical Name: The scientific name assigned using standard nomenclature, such as that established by the International Union of Pure and Applied Chemistry, reflecting the drug’s chemical structure. A drug has only one chemical name.

  • Generic Name: The official, nonproprietary name of a drug assigned by the government. They often sound more chemical and typically end with specific suffixes like −ol-ol, −ine-ine, −one-one, −pril-pril, or −sartan-sartan. They are usually written in lowercase.

  • Trade Name: Also known as the brand name, proprietary name, or product name. It is the catchy, short name given by the manufacturer and is often capitalized.

  • Metabolism: Also referred to as biotransformation, this is the chemical process of breaking down a drug, which occurs primarily in the liver.

  • Excretion: The removal of the drug from the body, most commonly through the urine.

  • Absorption: The process involving the movement of a substance from its site of administration across body membranes to the circulating fluids (bloodstream).

  • Distribution: How a drug travels through the body to reach its target cells after enters the bloodstream or is injected.

  • Half-life (t1/2t_{1/2}): The length of time required for the drug's plasma concentration to decrease by one-half (50%50\%) after administration.

  • Peak: The point in time when the drug is at its highest concentration in the bloodstream and its strongest effect.

  • Onset: The amount of time it takes after administration for the drug to start producing a therapeutic effect.

  • Duration: The total amount of time a drug continues to maintain its therapeutic effect.

  • Side Effect: An expected but unwanted effect resulting from drug therapy.

  • Adverse Effect: A harmful, serious, or dangerous reaction to a medication.

  • Black Box Warning: The strongest warning issued by the FDA regarding serious risks associated with a drug.

  • Contraindication: A specific reason or condition why a particular drug should not be used in a patient.

  • Interaction: Occurs when a drug, food, or another substance alters how a medication works in the body.

  • Combination Drug: A medication that contains more than one active generic ingredient.

Introduction to Pharmacology and Therapeutics

  • Etymology: The word pharmacology comes from two Greek words: pharmakonpharmakon (meaning "medicine") and logoslogos (meaning "study"). Therefore, pharmacology is the study of medicine.

  • Therapeutics: This field is concerned with the prevention of disease and the treatment of suffering.

  • Pharmacotherapy (Pharmacotherapeutics): This is the application of drugs for the specific purpose of treating disease and alleviating human suffering. Drugs are considered just one tool available to nurses for this purpose.

  • Biologics: These agents are naturally produced by microorganisms, the molecular machinery of cells, tissues, or organs. They are large, complex molecules or mixtures of molecules composed of living material.

    • Examples include hormones, vaccines, interferons, monoclonal antibodies, and natural blood products/components.

  • Biosimilars: These are biological products highly similar to an original "reference product" approved by the FDA, with no meaningful clinical differences in safety and effectiveness. Unlike the reference product, biosimilars do not undergo the same rigorous preclinical and clinical testing.

  • Complementary and Alternative Medicine (CAM): These therapies include herbs, natural plant extracts, vitamins, minerals, and dietary supplements. Many consider these to be outside mainstream Western healthcare practice.

Pharmacokinetics: The Movement of Drugs

  • Core Concept: Pharmacokinetics (from pharmacopharmaco + kineticskinetics, meaning "movement") describes how the body deals with medications. To produce an effect, drugs must cross multiple plasma membranes.

  • Barriers to Circulation and Target Cells:

    • Oral drugs must cross the plasma membranes of mucosal cells in the GI tract and capillary endothelial cells to enter the blood.

    • To leave the blood, they cross capillary cells again to enter the interstitial fluid and potentially enter the nucleus or other organelles.

  • Physiologic Processes Affecting Movement:

    • Stomach acid and digestive enzymes can break down enteral drugs.

    • Liver enzymes may chemically change molecules to be less active.

    • Phagocytes or immune responses may attempt to remove drugs seen as foreign.

    • Kidneys and the large intestine work to excrete the medication.

Crossing Plasma Membranes

  • Active Transport: Movement against a concentration or electrochemical gradient. It requires the expenditure of cellular energy. "Cotransport" involves moving two or more chemicals simultaneously.

  • Diffusion (Passive Transport): Movement from an area of high concentration to an area of low concentration without energy expenditure.

  • Membrane Characteristics: The lipid bilayer is lipophilic. Small, nonionized, lipid-soluble molecules pass easily via simple diffusion.

    • Small water-soluble agents (e.g., urea, alcohol, water) enter through membrane pores.

    • Large molecules, ionized drugs, and water-soluble agents have difficulty crossing and often require protein carriers or active transport.

Absorption and Bioavailability

  • Dissolution Rate: This determines how quickly a drug disintegrates and disperses into simpler forms. Rapid dissolution generally leads to faster absorption and a faster onset of action.

  • Bioavailability: The physiologic ability of a drug to reach its target cells and produce its effect. This varies by dosage form and the amount of drug that actually reaches the target location.

  • Negative Formulary: A list compiled by some states of trade-name drugs that pharmacists cannot substitute with generics because minor differences in bioavailability could adversely affect patients in critical condition.

  • Factors Influencing Absorption:

    • Drug Formulation: Liquids are absorbed faster than tablets/capsules.

    • Dose: Higher doses are generally absorbed faster.

    • Route: IV administration is very rapid as it enters the blood directly. Oral, topical, IM, and subcutaneous routes take longer.

    • Size: Smaller molecules are absorbed faster than larger ones.

    • Surface Area: Larger absorptive site surface areas result in faster absorption.

    • Digestive Motility: Changes in GI movement can speed up or slow down absorption.

    • Blood Flow: Greater blood flow at the site of administration increases absorption speed.

    • Lipid Solubility: Lipid-soluble drugs absorb faster than water-soluble ones.

    • pH and Ionization: Acids are absorbed better in acidic environments; bases are absorbed better in alkaline environments. For example, aspirin is nonionized and easily absorbed in the stomach's acid but becomes ionized and less absorbable in the small intestine's alkaline environment.

    • Interactions: Tetracyclines taken with food or drugs containing calcium, iron, or magnesium delay absorption. High-fat meals slow stomach motility.

Distribution and Binding

  • Blood Flow to Tissues: Distribution is easiest to organs with high blood supply (heart, liver, kidneys, brain) and more difficult for those with low supply (skin, bone, adipose tissue).

  • Accumulation and Storage: Tissues like bone marrow, teeth, eyes, and adipose tissue have a high affinity for certain drugs. Tetracycline accumulates in bones and teeth. Bisphosphonates can take over a decade to decline by half in the skeletal system.

  • Drug–Protein Complexes: Drugs bind reversibly to plasma proteins (especially albumin). These complexes are too large to cross membranes.

    • Only unbound (free) drugs can reach target cells or be excreted.

    • Example: Warfarin (Coumadin) is 99%99\% protein-bound.

  • Displacement Interactions: One drug can displace another from binding sites, raising levels of the free drug and causing toxicity. Example: Valproic acid or high-dose aspirin can displace warfarin, increasing hemorrhage risk.

  • Blood–Brain Barrier (BBB) and Fetal–Placental Barrier:

    • BBB: Prevents most chemicals and antitumor meds from entering the brain. Sedatives and anticonvulsants cross it easily.

    • Fetal–Placental Barrier: Prevents many harmful substances from reaching the fetus, though substances like alcohol, cocaine, caffeine, and certain prescriptions cross it easily and may cause harm.

Metabolism and the P450 System

  • Hepatic Microsomal Enzyme System: Also called the P450 system (Cytochrome P450 or CYP450). There are over 5050 types of CYP450 enzymes.

  • Primary Action: To inactivate drugs and accelerate excretion. However, some metabolites are more active than the parent drug (e.g., codeine is biotransformed into morphine).

  • Prodrugs: Drugs with no pharmacologic activity until they undergo metabolism (e.g., benazepril, losartan).

  • Induction vs. Inhibition:

    • Enzyme Induction: Some drugs increase metabolic activity. Example: Carbamazepine lowers the plasma levels of co-administered drugs. Other inducers: dexamethasone, modafinil, omeprazole, phenobarbital, rifampin.

    • Enzyme Inhibition: Drugs that reduce metabolic activity, potentially leading to toxic levels of other drugs. Example: Ketoconazole and other azole antifungals (clotrimazole, miconazole).

  • First-Pass Effect: Oral drugs enter the hepatic portal circulation and are often completely metabolized to inactive forms by the liver before reaching general circulation. This requires alternative routes like sublingual, rectal, or parenteral delivery for some drugs.

Excretion Mechanisms

  • Renal Excretion: The primary site of excretion is the kidney. Approximately 180 L180\,L of blood is filtered daily.

    • Small, free drugs and water-soluble agents are filtered at the glomerulus.

    • Large proteins and drug-protein complexes are not filtered.

    • pH Manipulation: To speed excretion of acidic drugs (like aspirin) in overdose, sodium bicarbonate is used to alkalize the urine, ionizing the drug and preventing reabsorption. To speed excretion of basic drugs (like diazepam), the filtrate is acidified.

  • Biliary Excretion: Drugs secreted into bile enter the duodenum. Some leave in feces, but many undergo enterohepatic recirculation, where they are recirculated with bile back to the liver, prolonging drug activity (common with cardiac glycosides and antibiotics).

  • Respiratory Excretion: Used for gaseous or volatile drugs. Rate depends on gas solubility and pulmonary blood flow. Lungs usually excrete drugs in their original nonmetabolized form.

  • Glandular Excretion: Drugs can be secreted into saliva, sweat, or breast milk. Basic drugs like morphine or codeine can reach high concentrations in breast milk.

Plasma Concentration and Therapeutic Range

  • Minimum Effective Concentration: The amount of drug required to produce a therapeutic effect.

  • Toxic Concentration: The level that results in serious adverse effects.

  • Therapeutic Range: The plasma drug concentration between the minimum effective and toxic concentrations.

  • Steady State (Plateau): Reached when the amount of drug administered equals the amount eliminated. This typically takes approximately four half-lives.

  • Loading Dose: A higher initial amount given to "prime" the bloodstream and reach the therapeutic range quickly. Followed by maintenance doses to keep the level in the plateau.

Pharmacodynamics: The Magnitude of Response

  • Potency: A drug that is more potent produces a therapeutic effect at a lower dose than another drug in the same class.

  • Efficacy: The magnitude of the maximal response that can be produced from a particular drug.

  • Receptor Theory: Most drugs bind to receptors (cellular macromolecules) to initiate effects. Standard receptors bind endogenous molecules like hormones and neurotransmitters.

    • Agonist: A drug that produces a response mimicking the endogenous substance (e.g., bethanechol mimics acetylcholine).

    • Partial Agonist: Produces a weaker response than a full agonist.

    • Antagonist: A drug that occupies a receptor to prevent an endogenous chemical from acting. Competitive antagonists compete for the same site.

    • Functional Antagonist: Inhibits effects not by receptor competition but by changing pharmacokinetics (e.g., slowing absorption or speeding excretion).

  • Nonspecific Cellular Responses: Drugs that act independently of receptors, such as general anesthetics, ethyl alcohol, and osmotic diuretics.

  • Interpatient Variability: The Median Effective Dose (ED50ED_{50} ) is the dose required to produce a specific response in 50%50\% of a group. This is often the "standard" or "average" dose reported in drug guides.

Lifespan Considerations: Pregnancy and Lactation

  • Physiologic Changes in Pregnancy:

    • Absorption: Increased progesterone delays gastric emptying and increases tidal volume (enhancing absorption of inhaled drugs).

    • Distribution/Metabolism: Increased blood volume dilutes drugs; less albumin increases free drug levels. Metabolism of anticonvulsants (carbamazepine, phenytoin) often increases, requiring higher doses.

    • Excretion: Renal blood flow increases by over 50%50\% by the third trimester, increasing drug excretion.

  • Teratogen: A substance or organism that causes permanent abnormalities, growth retardation, or death to a fetus. The baseline incidence is 3%3\%.

  • Lactation:

    • If possible, drugs should be administered immediately after breastfeeding or when the infant will sleep a long time.

    • Short half-life drugs and drugs with high protein-binding are preferred as they are less likely to accumulate in milk.

Lifespan Considerations: Pediatric Patients

  • Infants (Birth to 1212 months): The first 2828 days are the neonatal period. Use the vastus lateralis for IM injections to avoid the sciatic nerve. Use a tuberculin syringe for volumes less than 1 mL1\,mL.

  • Toddlers (11 to 33 years): Poisoning is a major concern. Education should focus on child-resistant containers and the Poison Control Center number. For bad-tasting meds, use vehicles like jam or fruit puree, but avoid milk or orange juice to prevent negative associations.

  • Preschoolers (33 to 55 years): Some can comprehend the link between meds and health. Use play-acting with dolls to reduce anxiety.

  • School-age Child (66 to 1212 years): Provide choices (e.g., which drink to follow a tablet) to give a sense of control and encourage cooperation.

  • Iron Poisoning: A leading cause of death in children under 66. Found in prenatal and pediatric vitamins. As few as five iron tablets can be fatal. Symptoms include nausea, vomiting, GI bleeding, and coma.

  • Adolescents (1313 to 1616 years): Emphasis on privacy and independence. Major concerns include skin issues, contraception, and substance abuse. Opioid misuse deaths in teens increased by 268%268\% from 19991999 to 20162016.

Lifespan Considerations: Geriatric Patients

  • Polypharmacy: The concurrent use of multiple drugs, common in older adults, drastically increases interaction risk.

  • Physiologic Decline:

    • Absorption: Slower due to decreased motility and blood flow; increased gastric pH slows dissolution of some tablets.

    • Distribution: Increased body fat stores lipid-soluble drugs longer; decreased total body water increases toxicity risk of water-soluble drugs; decreased albumin increases free drug levels.

    • Metabolism: Reduced hepatic blood flow and enzyme production increase drug half-life.

    • Excretion: Reduced renal function is the most common cause of adverse drug reactions in older adults.

  • Beers Criteria: A list of Potentially Inappropriate Medications (PIMs) specifically for older adults due to safety concerns like sedation, confusion, and fractures.

Pharmacogenomics and Future Trends

  • Pharmacogenetics: Examines the role of heredity in drug response. Identifies specific genetic differences in drug-metabolizing enzymes.

  • Pharmacogenomics: Using a patient's unique genetic profile to select the most effective drugs with the best safety profile. This is currently used or studied in cancer, psychiatry, infection, and pain management.

  • Barriers: Cost, lack of extensive clinical trials for all groups, and ethical issues related to genetic markers.